Oculis to Present at Key Investor Conference
Oculis Holding AG (Nasdaq: OCS; Iceland: OCS) is gearing up for a significant opportunity as it announces its participation in an upcoming investor conference. This event promises to be an essential platform for discussing the company's pioneering work in biopharmaceuticals aimed at enhancing eye care and preserving sight.
Details of the Upcoming Presentation
The Leerink Global Healthcare Conference is set to feature Oculis prominently, with the presentation led by Sylvia Cheung, the Chief Financial Officer. Investors looking to understand Oculis' strategic direction and product innovations should circle their calendars for the presentation scheduled for March 11, 2025, at 3:00 PM ET.
During the conference, Oculis will engage in one-on-one meetings, allowing attendees to gain deeper insights into the company's current and future projects. Interested participants can reach out to their contacts at the sponsoring institution to arrange these meaningful discussions.
Accessing the Live Webcast
For those unable to attend in person, Oculis has made arrangements for a live webcast of the fireside chat. This will be available on the Oculis website under the Investors & Media section. This accessibility ensures that stakeholders can stay informed about the company's ongoing initiatives and strategic goals without any hurdles.
About Oculis
Oculis is more than just a biopharmaceutical company; it is a dedicated entity committed to transforming eye care globally. By developing advanced therapies, Oculis endeavors to make a significant impact on the treatment of various eye diseases, enhancing the quality of life for countless individuals.
The company has developed a highly differentiated pipeline featuring several unique product candidates:
- OCS-01: A topical eye drop aimed at treating diabetic macular edema, representing a potential breakthrough in how this condition is managed.
- Privosegtor (OCS-05): A neuroprotective candidate designed for acute optic neuritis, with the potential for application across a spectrum of neuro-ophthalmic diseases.
- Licaminlimab (OCS-02): A topical biologic anti-TNF? eye drop candidate targeting dry eye disease, which can substantially improve patient comfort and eyesight.
Oculis operates from its headquarters in Switzerland, with additional offices in the United States and Iceland. The leadership team, backed by prominent healthcare investors, brings a wealth of experience and a proven track record to the forefront of the company’s operations.
Oculis Contacts
If you wish to learn more about Oculis or its initiatives, you can reach out to:
Ms. Sylvia Cheung, CFO
Email: sylvia.cheung@oculis.com
For investor relations, contact LifeSci Advisors:
Corey Davis, Ph.D.
Email: cdavis@lifesciadvisors.com
Frequently Asked Questions
What is the focus of Oculis Holding AG?
Oculis focuses on biopharmaceuticals targeted at saving sight and improving eye care through innovative product development.
When will Oculis present at the investor conference?
Oculis will present at the Leerink Global Healthcare Conference on March 11, 2025, at 3:00 PM ET.
How can investors engage with Oculis at the conference?
Investors can request one-on-one meetings with Oculis representatives during the conference through their sponsoring institution contacts.
What are some of Oculis’ key product candidates?
Oculis' notable product candidates include OCS-01 for diabetic macular edema and Licaminlimab (OCS-02) for dry eye disease.
How can I find more information about Oculis?
More information is available on Oculis' official website in the Investors & Media section.
